186 related articles for article (PubMed ID: 28707375)
41. Predictors of clinical outcomes after coronary implantation of bioresorbable polymer sirolimus-eluting Ultimaster stents in all-comers: A report of 1,727 cases.
Tadano Y; Kotani JI; Kashima Y; Hachinohe D; Watanabe T; Sugie T; Kaneko U; Kobayashi K; Kanno D; Fujita T
Catheter Cardiovasc Interv; 2019 Jul; 94(1):91-97. PubMed ID: 30636371
[TBL] [Abstract][Full Text] [Related]
42. Final five-year outcomes after implantation of biodegradable polymer-coated biolimus-eluting stents versus durable polymer-coated sirolimus-eluting stents.
Jakobsen L; Christiansen EH; Maeng M; Hansen KN; Kristensen SD; Bøtker HE; Terkelsen CJ; Jensen SE; Raungaard B; Madsen M; Lassen JF; Jensen LO
EuroIntervention; 2017 Dec; 13(11):1336-1344. PubMed ID: 28846543
[TBL] [Abstract][Full Text] [Related]
43. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
44. Long-term clinical outcome of rotational atherectomy followed by drug-eluting stent implantation in complex calcified coronary lesions.
Abdel-Wahab M; Baev R; Dieker P; Kassner G; Khattab AA; Toelg R; Sulimov D; Geist V; Richardt G
Catheter Cardiovasc Interv; 2013 Feb; 81(2):285-91. PubMed ID: 22431433
[TBL] [Abstract][Full Text] [Related]
45. A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy.
Jiménez VA; Iñiguez A; Baz JA; Valdés M; Ortiz A; Vuilliomenet A; Mainar V; Dudek D; Banai S; Tüller D; Bonnet JL; De Miguel A; Bastos G; Wijns W; Saito S
Cardiovasc Revasc Med; 2016 Sep; 17(6):355-61. PubMed ID: 27156201
[TBL] [Abstract][Full Text] [Related]
46. First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter.
Price MJ; Saito S; Shlofmitz RA; Spriggs DJ; Attubato M; McLaurin B; Popma Almonacid A; Brar S; Liu M; Moe E; Mehran R
JACC Cardiovasc Interv; 2017 Jul; 10(14):1381-1388. PubMed ID: 28728650
[TBL] [Abstract][Full Text] [Related]
47. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
[TBL] [Abstract][Full Text] [Related]
48. Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.
Raungaard B; Christiansen EH; Bøtker HE; Hansen HS; Ravkilde J; Thuesen L; Aarøe J; Villadsen AB; Terkelsen CJ; Krusell LR; Maeng M; Kristensen SD; Veien KT; Hansen KN; Junker A; Madsen M; Andersen SL; Jensen SE; Jensen LO;
JACC Cardiovasc Interv; 2017 Feb; 10(3):255-264. PubMed ID: 28109874
[TBL] [Abstract][Full Text] [Related]
49. Comparison of two biodegradable-polymer-based sirolimus-eluting stents with varying elution and absorption kinetics in patients with acute myocardial infarction: A subgroup analysis of the PANDA III trial.
Guan C; Xu B; Qiao S; Qin L; Li Y; Li Z; Guo Y; Sun Z; Song L; Gao R;
Catheter Cardiovasc Interv; 2017 Mar; 89(S1):520-527. PubMed ID: 28109057
[TBL] [Abstract][Full Text] [Related]
50. Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial.
Kufner S; Byrne RA; Valeskini M; Schulz S; Ibrahim T; Hoppmann P; Schneider S; Laugwitz KL; Schunkert H; Kastrati A;
EuroIntervention; 2016 Mar; 11(12):1372-9. PubMed ID: 25405657
[TBL] [Abstract][Full Text] [Related]
51. Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: two-year results from a prospective patient-level pooled analysis of TARGET trials.
Gao Z; Zhang R; Xu B; Yang Y; Ma C; Li H; Chen S; Han Y; Yuan Z; Lansky AJ; Guan C; Leon MB; Gao R;
Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():734-43. PubMed ID: 25678281
[TBL] [Abstract][Full Text] [Related]
52. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
[TBL] [Abstract][Full Text] [Related]
53. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
Gao RL; Xu B; Lansky AJ; Yang YJ; Ma CS; Han YL; Chen SL; Li H; Zhang RY; Fu GS; Yuan ZY; Jiang H; Huo Y; Li W; Zhang YJ; Leon MB;
EuroIntervention; 2013 May; 9(1):75-83. PubMed ID: 23685298
[TBL] [Abstract][Full Text] [Related]
54. Impact of Diabetes on Clinical Outcomes After Polymer-Free Amphilimus- and Biolimus-Eluting Stent Implantation.
Chiarito M; Stefanini GG; Godino C; Sardella G;
JACC Cardiovasc Interv; 2019 Sep; 12(17):1745-1747. PubMed ID: 31126886
[No Abstract] [Full Text] [Related]
55. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
[TBL] [Abstract][Full Text] [Related]
56. Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study.
Li Y; Han Y; Zhang L; Jing Q; Wang X; Yan G; Ma Y; Wang G; Wang S; Chen X; Yang L; Zhu G; Liu H; Jiang T
Catheter Cardiovasc Interv; 2013 Jun; 81(7):1127-33. PubMed ID: 22945767
[TBL] [Abstract][Full Text] [Related]
57. Drug-eluting stents in patients on chronic hemodialysis: paclitaxel-eluting stents vs. limus-eluting stents.
Sardi GL; Loh JP; Torguson R; Laynez-Carnicero A; Kitabata H; Xue Z; Satler LF; Pichard AD; Waksman R
Cardiovasc Revasc Med; 2014 Mar; 15(2):86-91. PubMed ID: 24684759
[TBL] [Abstract][Full Text] [Related]
58. Five-year follow-up of polymer-free sirolimus- and probucol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with st-elevation myocardial infarction.
Colleran R; Kufner S; Harada Y; Giacoppo D; Cassese S; Repp J; Wiebe J; Lohaus R; Lahmann A; Schneider S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA;
Catheter Cardiovasc Interv; 2017 Feb; 89(3):367-374. PubMed ID: 27377301
[TBL] [Abstract][Full Text] [Related]
59. The BIOFLOW-III Italian Satellite Registry: 18-month results of the Orsiro stent in an all-comer high-risk population.
Bartorelli AL; Versaci F; Briguori C; Tomai F; Aprigliano G; Poli A; Vigna C; Marinucci L; My L; Masi F; Turturo M
J Cardiovasc Med (Hagerstown); 2019 Jul; 20(7):464-470. PubMed ID: 30994511
[TBL] [Abstract][Full Text] [Related]
60. Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial.
Kufner S; Byrne RA; de Waha A; Schulz S; Joner M; Laugwitz KL; Kastrati A;
Cardiovasc Revasc Med; 2014 Mar; 15(2):69-75. PubMed ID: 24684757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
